News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Faces New Hurdle for Degludec



7/18/2012 7:00:44 AM

BAGSVAERD, DENMARK--(Marketwire - July 18, 2012) -

Company Announcement No 46 / 2012: http://hugin.info/2013/R/1627515/520914.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1627515]


Further information:

Media:
Mike Rulis
Tel: (+45) 3079 3573
Email Contact

Investors:
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4303
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact


Read at BioSpace.com
Read at Chicago Tribune
Read at Reuters
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES